The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
By Guy M. McKhann, David S. Knopman, H. Chertkow, Bradley T. Hyman, Clifford R. Jack Jr., C. H. Kawas, William E. Klunk, W. Koroshetz, Jennifer J Manly, Richard P. Mayeux and 8 more. Alzheimer's & Dementia, 2011
16,320 citations recorded by the source corpus.
The National Institute on Aging and the Alzheimer's Association charged a workgroup with the task of revising the 1984 criteria for Alzheimer's disease (AD) dementia. The workgroup sought to ensure that the revised criteria would be flexible enough to be used by both general healthcare providers without access to neuropsychological testing, advanced imaging, and cerebrospinal fluid measures, and specialized investigators involved in research or in clinical trial studies who would have these tools available. We present criteria for all‐cause dementia and for AD dementia. We retained the general framework of probable AD dementia from the 1984 criteria. On the basis of the past 27 years of experience, we made several changes in the clinical criteria for the diagnosis. We also retained the term possible AD dementia, but redefined it in a manner more focused than before. Biomarker evidence was also integrated into the diagnostic formulations for probable and possible AD dementia for use in research settings. The core clinical criteria for AD dementia will continue to be the cornerstone of the diagnosis in clinical practice, but biomarker evidence is expected to enhance the pathophysiological specificity of the diagnosis of AD dementia. Much work lies ahead for validating the biomarker diagnosis of AD dementia.
Subfields: Geriatrics and Gerontology, Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/37d2d04f8c09da1f0cf8434a38a51841b5b703bf
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Geriatrics and Gerontology
In Physiology
- Christos Davatzikos
- D. Holtzman
- Clifford R. Jack Jr.
- J. Long
- Ronald C. Petersen
- John Hardy
- Reisa A. Sperling
- Yaakov Stern
In Psychiatry and Mental health
- Christos Davatzikos
- Ronald C. Petersen
- Clifford R. Jack Jr.
- J. Long
- Yaakov Stern
- D. Holtzman
- C. Zhong
- Zhichun Chen
Citations in the corpus
- Clinical Practice Guideline (2014, positive): “A complete evaluation for cognitive disorders is beyond the scope of this guideline; screening guidelines for Alzheimer’s disease and mild cognitive impairment have been previously published.(64,65) However, a rapid screening test may facilitate the workup of tinnitus and guide appropriate referrals”
- National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2011, neutral): “‘‘Alzheimer’s disease’’ refers to a constellation of cognitive and behavioral changes that are typical for patients who have substantial amounts of its hallmark lesions [6, 39].”
- Epidemiology of Alzheimer Disease (2012, neutral): “The NINCDS-ADRDA criteria have very recently been updated (McKhann et al. 2011).”
- Alzheimer's disease diagnostics by adaptation of 3D convolutional network (2016, background): “Several popular non-invasive neuroimaging tools, such as structural MRI (sMRI), functional MRI (fMRI), and positron emission tomography (PET), have been investigated for developing such a system [4, 5].”
- Recommendations for the nomenclature of cognitive change associated with anaesthesia and surgery—2018 (2018, positive): “Commentary will, no doubt, continue, and this nomenclature will be likely to evolve, as has been the case for the NIA-AA nomenclature.(13,14) This terminology applies the rubric used by the American Psychiatric Association, whereby a multidisciplinary team work to produce a document clearly describi”
- The neuropathological diagnosis of Alzheimer’s disease (2019, background): “Ultimately these criteria were revised in the 2012 NIA-AA Guidelines as it became more universally acknowledged that AD pathology can be present in the absence of clinical symptoms though there are updated clinical guidelines available for ascribing dementia to AD pathology before death [111].”
- Classifying neurocognitive disorders: the DSM-5 approach (2014, background): “…discussions with experts from diverse fields to harmonize the DSM criteria with cri‑ teria developed by other expert groups, such as the NIA– AA, 20,27 the frontotemporal dementia expert group, 28,29 the consortium on DLB, 30 the VASCOG working group, 31 the Movement Disorder Study Task Force on…”
- Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer’s disease (2017, background): “All participants met clinical criteria for probable Alzheimer’s disease dementia (n = 35; McKhann et al., 2011) or mild cognitive impairment (MCI) due to Alzheimer’s disease (n = 5; Albert et al.”
- A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer’s disease (2014, positive): “The US National Institute on Aging-Alzheimer’s Association (NIA-AA) group proposed (1) the preclinical stage of AD (no impairment in cognition on standard assessments and biomarker evidence for AD), (2) mild cognitive impairment (MCI) due to AD (impairment on memory or other domains of cognition on ”